Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis
Objective: Daprodustat is a novel oral agent in treating anemia of chronic kidney disease (CKD), and several clinical trials have been conducted to compare daprodustat with recombinant human erythropoietin (rhEPO) or placebo. Our systematic review aimed to investigate the efficacy and safety of dapr...
Main Authors: | Qiyan Zheng, Yahui Wang, Huisheng Yang, Luying Sun, Xinwen Fu, Ruojun Wei, Yu Ning Liu, Wei Jing Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2020.573645/full |
Similar Items
-
Hypoxia-inducible factor for the treatment of anemia in chronic kidney disease
by: O.O. Melnyk
Published: (2018-10-01) -
Anemia is associated with increased risk of contrast‑induced acute kidney injury: A Systematic Review and Meta-analysis
by: Wei Liang, et al.
Published: (2021-01-01) -
Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
by: Ishii T, et al.
Published: (2021-02-01) -
Hemoglobin targets for the anemia in patients with dialysis-dependent chronic kidney disease: a meta-analysis of randomized, controlled trials
by: Yuqiu Ye, et al.
Published: (2018-10-01) -
Maternal Anemia and Pregnancy outcomes: a Systematic Review and Meta-Analysis
by: Shoboo Rahmati, et al.
Published: (2016-08-01)